In our study, using models of mouse and human bladder cancer, we demonstrated that the combined use of local HDACi and systemic anti-PD-1 blockade was effective at inducing anti-tumor responses with durable anti-tumor immunity that was associated with the upregulation of genes responsible for mediating immunorecognition, NKG2D ligands and HSP70. This evidence concerns the gene KLRK1 and urinary bladder cancer.